Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Biocorp
  6. News
  7. Summary
    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
Real-time Euronext Paris  -  11:35 2022-11-30 am EST
15.25 EUR   -0.65%
10/26BIOCORP, Novo Nordisk Agree to Commercialize Smart Sensor for Recording Insulin Injection Data
MT
10/26Biocorp and Novo Nordisk Strengthen Their Partnership with A New Agreement on Mallya Smart Sensor
CI
10/18Becton, Dickinson Signs Agreement With Biocorp to Track Adherence for Self-Administered Drug Therapies
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

France's Biocorp Gets CE Marking for Accessory Medical Device for Sanofi's Insulin Injection Pens

09/19/2022 | 03:28am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOCORP -0.65% 15.25 Real-time Quote.-47.07%
SANOFI -1.94% 86.48 Real-time Quote.-0.44%
All news about BIOCORP
10/26BIOCORP, Novo Nordisk Agree to Commercialize Smart Sensor for Recording Insulin Injecti..
MT
10/26Biocorp and Novo Nordisk Strengthen Their Partnership with A New Agreement on Mallya Sm..
CI
10/18Becton, Dickinson Signs Agreement With Biocorp to Track Adherence for Self-Administered..
MT
10/18Biocorp, BD Sign Deal to Track Self-administered Injection Data
MT
10/18Becton, Dickinson and Company and Biocorp Sign Agreement to Bring Connectivity, Traceab..
CI
10/10Merck KGaA, Biocorp to Co-develop New Bluetooth-enabled Drug Delivery Device
MT
09/29Biocorp Production Reports Earnings Results for the Half Year Ended June 30, 2022
CI
09/29BIOCORP : 1st-half-year results
CO
09/19France's Biocorp Gets CE Marking for Accessory Medical Device for Sanofi's Insulin Inje..
MT
04/05Biocorp Production Reports Earnings Results for the Full Year Ended December 31, 2021
CI
More news
Financials
Sales 2022 12,5 M 13,0 M 13,0 M
Net income 2022 0,80 M 0,83 M 0,83 M
Net Debt 2022 4,38 M 4,53 M 4,53 M
P/E ratio 2022 83,0x
Yield 2022 0,20%
Capitalization 67,5 M 69,8 M 69,8 M
EV / Sales 2022 5,74x
EV / Sales 2023 4,21x
Nbr of Employees 74
Free-Float 54,4%
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 15,35 €
Average target price 37,57 €
Spread / Average Target 145%
EPS Revisions
Managers and Directors
Eric Dessertenne Chief Executive Officer
StÚphane Chabanais VP-Finance, Director-Finance & Administration
Jacques Gardette Chairman
Alain Marcoz Director-Research & Development
Jean-Yves Berthon Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOCORP-47.07%70
JOHNSON & JOHNSON2.93%460 384
ELI LILLY AND COMPANY32.42%345 817
ABBVIE INC.16.84%279 679
PFIZER, INC.-16.19%277 803
NOVO NORDISK A/S19.71%276 497